On March, 12 WallStreet expected Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s earnings report, as reported by RTT. Analysts predict $-0.75 EPS. That’s $0.08 down or 11.94 % from 2018’s earnings of $-0.67. After $-0.56 EPS was revealed previous quarter, analysts now see negative EPS growth of 33.93 % for Madrigal Pharmaceuticals, Inc.. Ticker’s shares touched $136.1 during the last trading session after 0.15% change.Currently Madrigal Pharmaceuticals, Inc. is uptrending after 37.05% change in last February 26, 2018. MDGL has also 151,889 shares volume. The stock outperformed the S&P 500 by 37.05%.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.The firm is valued at $2.10 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia.Currently it has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

For more Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news released recently go to: Seekingalpha.com, Benzinga.com, Nasdaq.com, Seekingalpha.com or Schaeffersresearch.com. The titles are as follows: “Raymond James upgrades Viking Therapeutics to Strong Buy; shares up 7% premarket – Seeking Alpha” released on November 19, 2018, “26 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” on February 12, 2019, “Noteworthy Thursday Option Activity: FICO, MDGL, GTLS – Nasdaq” with a publish date: February 14, 2019, “Viking Therapeutics, Madrigal move up as Gilead liver drug fails to meet goals – Seeking Alpha” and the last “Analysts Lower Expectations on Pharma Stocks IRWD and MDGL – Schaeffers Research” with publication date: November 19, 2018.